64Cu Treatment Planning and 67Cu Therapy with Radiolabeled [64Cu/67Cu]MeCOSar-Octreotate in Subjects with Unresectable Multifocal Meningioma: Initial Results for Human Imaging, Safety, Biodistribution, and Radiation Dosimetry

Dale L. Bailey; Kathy P. Willowson; Matthew Harris; Colin Biggin; Alireza Aslani; Nigel A. Lengkeek; Jon Stoner; M. Enid Eslick; Harry Marquis; Michelle Parker; Paul J. Roach; Geoffrey P. Schembri

doi:10.2967/jnumed.122.264586

Research ArticleClinical Investigation

⁶⁴Cu Treatment Planning and ⁶⁷Cu Therapy with Radiolabeled [⁶⁴Cu/⁶⁷Cu]MeCOSar-Octreotate in Subjects with Unresectable Multifocal Meningioma: Initial Results for Human Imaging, Safety, Biodistribution, and Radiation Dosimetry

Dale L. Bailey, Kathy P. Willowson, Matthew Harris, Colin Biggin, Alireza Aslani, Nigel A. Lengkeek, Jon Stoner, M. Enid Eslick, Harry Marquis, Michelle Parker, Paul J. Roach and Geoffrey P. Schembri

Journal of Nuclear Medicine May 2023, 64 (5) 704-710; DOI: https://doi.org/10.2967/jnumed.122.264586

Dale L. Bailey

1Department of Nuclear Medicine, Royal North Shore Hospital, Sydney, New South Wales, Australia;

2Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia;

3Sydney Vital Translational Cancer Research Centre, Sydney, New South Wales, Australia;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Kathy P. Willowson

1Department of Nuclear Medicine, Royal North Shore Hospital, Sydney, New South Wales, Australia;

4Institute of Medical Physics, University of Sydney, Sydney, New South Wales, Australia;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Matthew Harris

5Clarity Pharmaceuticals, Sydney, New South Wales, Australia;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Colin Biggin

5Clarity Pharmaceuticals, Sydney, New South Wales, Australia;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Alireza Aslani

1Department of Nuclear Medicine, Royal North Shore Hospital, Sydney, New South Wales, Australia;

2Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Nigel A. Lengkeek

6ANSTO Biosciences, Sydney, New South Wales, Australia; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jon Stoner

7Idaho Accelerator Center, Idaho State University, Pocatello, Idaho

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

M. Enid Eslick

1Department of Nuclear Medicine, Royal North Shore Hospital, Sydney, New South Wales, Australia;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Harry Marquis

3Sydney Vital Translational Cancer Research Centre, Sydney, New South Wales, Australia;

4Institute of Medical Physics, University of Sydney, Sydney, New South Wales, Australia;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Michelle Parker

5Clarity Pharmaceuticals, Sydney, New South Wales, Australia;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Paul J. Roach

1Department of Nuclear Medicine, Royal North Shore Hospital, Sydney, New South Wales, Australia;

2Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Geoffrey P. Schembri

1Department of Nuclear Medicine, Royal North Shore Hospital, Sydney, New South Wales, Australia;

2Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Supplemental
Info & Metrics
PDF

Data supplements

Supplemental Data

Files in this Data Supplement:

Supplemental Data

PreviousNext

In this issue

Journal of Nuclear Medicine

Vol. 64, Issue 5

May 1, 2023

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Complete Issue (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following 64Cu Treatment Planning and 67Cu Therapy with Radiolabeled [64Cu/67Cu]MeCOSar-Octreotate in Subjects with Unresectable Multifocal Meningioma: Initial Results for Human Imaging, Safety, Biodistribution, and Radiation Dosimetry

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

⁶⁴Cu Treatment Planning and ⁶⁷Cu Therapy with Radiolabeled [⁶⁴Cu/⁶⁷Cu]MeCOSar-Octreotate in Subjects with Unresectable Multifocal Meningioma: Initial Results for Human Imaging, Safety, Biodistribution, and Radiation Dosimetry

Dale L. Bailey, Kathy P. Willowson, Matthew Harris, Colin Biggin, Alireza Aslani, Nigel A. Lengkeek, Jon Stoner, M. Enid Eslick, Harry Marquis, Michelle Parker, Paul J. Roach, Geoffrey P. Schembri

Journal of Nuclear Medicine May 2023, 64 (5) 704-710; DOI: 10.2967/jnumed.122.264586

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Dale L. Bailey, Kathy P. Willowson, Matthew Harris, Colin Biggin, Alireza Aslani, Nigel A. Lengkeek, Jon Stoner, M. Enid Eslick, Harry Marquis, Michelle Parker, Paul J. Roach, Geoffrey P. Schembri

Journal of Nuclear Medicine May 2023, 64 (5) 704-710; DOI: 10.2967/jnumed.122.264586

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Bookmark this article

User Name *

Password *

Remember my user name & password.

Jump to section

Article
Figures & Data
Supplemental
Info & Metrics
PDF

PubMed
Google Scholar

Cited By...

Potential of 188Re as an Alternative to 177Lu and Dosimetric Consequences

Google Scholar

Keywords

radionuclide therapy
Copper radionuclides
dosimetry
meningioma
safety
theranostics

Main menu

User menu

Search

⁶⁴Cu Treatment Planning and ⁶⁷Cu Therapy with Radiolabeled [⁶⁴Cu/⁶⁷Cu]MeCOSar-Octreotate in Subjects with Unresectable Multifocal Meningioma: Initial Results for Human Imaging, Safety, Biodistribution, and Radiation Dosimetry

Data supplements

Supplemental Data

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Keywords